First Trust Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

First Trust Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.2M	Buy	3,041,829 +431,103	+17%	+$1.44M	0.01%	1174
2026 Q1	$8.01M	Buy	2,610,726 +344,035	+15%	+$1.33M	0.01%	1202
2025 Q4	$9.27M	Buy	2,266,691 +469,486	+26%	+$2.33M	0.01%	1133
2025 Q3	$8.77M	Sell	1,797,205 -83,085	-4%	-$436K	0.01%	1133
2025 Q2	$9.51M	Buy	1,880,290 +848,791	+82%	+$4.17M	0.01%	1104
2025 Q1	$5.46M	Buy	+1,031,499	New	+$7.52M	﹤0.01%	1272
2024 Q3	–	Sell	-94,854	Closed	-$711K	–	2467
2024 Q2	$711K	Sell	94,854 -282,871	-75%	-$2.47M	﹤0.01%	2045
2024 Q1	$3.77M	Buy	377,725 +125,032	+49%	+$1.39M	﹤0.01%	1441
2023 Q4	$2.49M	Buy	252,693 +18,271	+8%	+$130K	﹤0.01%	1622
2023 Q3	$1.79M	Buy	234,422 +188,685	+413%	+$1.88M	﹤0.01%	1727
2023 Q2	$342K	Buy	+45,737	New	+$320K	﹤0.01%	2220
2023 Q1	–	Sell	-241,147	Closed	-$1.86M	–	2455
2022 Q4	$1.86M	Buy	241,147 +111,709	+86%	+$1.1M	﹤0.01%	1725
2022 Q3	$1.38M	Buy	+129,438	New	+$1.31M	﹤0.01%	1867

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

First Trust Advisors's RXRX Position: Q2 2026 in Review

First Trust Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 17% in Q2 2026, buying an estimated $1.44M and bringing the position to 3,041,829 shares worth $11.2M. The position accounts for 0.01% of the portfolio, ranked #1174.

First Trust Advisors first reported a position in RXRX in Q3 2022 and has held it in 13 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

First Trust Advisors held 3,041,829 shares of Recursion Pharmaceuticals worth $11.2M as of Q2 2026.
First Trust Advisors bought 431,103 Recursion Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
Recursion Pharmaceuticals made up 0.01% of First Trust Advisors's portfolio in Q2 2026, its #1174 holding.
First Trust Advisors first reported a position in Recursion Pharmaceuticals in Q3 2022 and has held it in 13 quarters since.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.